Welcome to our dedicated page for Generate Biomedicines SEC filings (Ticker: GENB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Generate Biomedicines, Inc. filings document public-company events, financial results, governance changes, capital structure, and clinical portfolio disclosures. The company's Form 8-K reports include quarterly results and business updates covering its generative biology platform and named programs such as GB-0895, GB-4362, and GB-5267.
Filings also describe IPO-related governance documents, including the amended and restated certificate of incorporation and bylaws, authorized common and preferred stock, stockholder meeting procedures, advance-notice provisions, and board authority over undesignated preferred stock. Registration and event disclosures provide formal records of the company's transition to a Nasdaq-listed clinical-stage biotechnology issuer.
Generate Biomedicines, Inc. reported that Chief Legal Officer & General Counsel Martin Sean received a grant of stock options covering 190,034 shares on February 26, 2026. The award was recorded as a grant or other acquisition, not an open-market purchase. According to the disclosure, the options vest in 48 equal monthly installments starting after February 19, 2026, and each installment requires his continued service on the relevant vesting date.
Generate Biomedicines director Nancy A. Simonian received a stock option grant for 29,561 shares of common stock at an exercise price of $0.00 per share. According to the filing, the option vests in full on February 19, 2027, subject to her continued service on that vesting date.
Generate Biomedicines, Inc. executive Jason Silvers, President & CFO, reported several equity transactions. On March 2, 2026, accounts for his daughter and son bought a total of 2,000 shares of common stock in open-market purchases at $16.00 per share, reported as indirect ownership.
On February 26, 2026, he also received two grants of stock options. One option covers 295,608 shares, vesting in two equal installments on February 19, 2029 and February 19, 2030. The other covers 274,493 shares, vesting in forty-eight equal monthly installments following February 19, 2026, in each case contingent on continued service.
Generate Biomedicines, Inc. reported multiple insider transactions involving entities affiliated with Flagship Pioneering. On March 2, 2026, shares of Series A, B and C preferred stock held by several Flagship funds automatically converted into common stock on a one-for-1.5190 basis upon the closing of the company’s initial public offering.
On the same date, Flagship Pioneering Fund VII, L.P., FPN II, L.P. and Pioneering Medicines 02, LLC each purchased 1,562,500 shares of common stock at $16.00 per share, totaling 4,687,500 shares, all reported as indirect ownership. Separately, on February 26, 2026, Noubar Afeyan received a stock option for 29,561 shares, vesting in full on February 19, 2027, contingent on continued service.
Generate Biomedicines Chief Technology Officer Gevorg Grigoryan reported two grants of stock options to acquire company shares. One option covers 295,608 shares and vests in two equal installments on February 19, 2029 and February 19, 2030, subject to continued service. A second option covers 196,368 shares and vests in forty-eight equal monthly installments following February 19, 2026, also conditioned on his continued service. Both awards are recorded at an exercise price of $0.00 per share, reflecting their nature as compensatory grants rather than open-market purchases.
Generate Biomedicines, Inc. director and CEO Michael Nally reported several insider equity transactions. An entity associated with him, the MTN 2024 GST Trust, converted 1,000,000 shares of Series A Preferred Stock into 658,327 shares of Common Stock at no per-share price upon the company’s initial public offering on March 2, 2026, and he disclaims beneficial ownership of those trust-held shares except for any pecuniary interest.
Separately, Nally received two direct stock option awards, each covering 844,595 shares, on February 26, 2026, as grants at a stated exercise price of $0.00 per share. One option vests in two equal installments on February 19, 2029 and February 19, 2030, and the other vests in 48 equal monthly installments after February 19, 2026, in each case subject to his continued service. As of February 26, 2026, he held 552,707 shares of Common Stock directly and 999,793 shares indirectly through the MTN 2024 GRAT.
Generate Biomedicines director Jane L. Mendillo reported two transactions involving the company’s securities. On March 2, 2026, she made an open-market purchase of 1,500 shares of Common Stock at $16.00 per share, bringing her directly held common shares to 1,500.
On February 26, 2026, she also received a grant of 29,561 stock options with an exercise price of $0.00. According to the disclosure, the shares underlying this option vest in full on February 19, 2027, subject to her continued service with the company on that vesting date.
Fanucci Marsha reported acquisition or exercise transactions in this Form 4 filing.
Generate Biomedicines, Inc. director Marsha Fanucci reported receiving a stock option grant for 29,561 shares on February 26, 2026. The option has a price per share of $0.00, reflecting a compensatory award rather than an open-market purchase. These option shares vest in full on February 19, 2027, if she continues in service through that date.
Generate Biomedicines, Inc. director Parker Paul Gray received a grant of stock options covering 29,561 shares on February 26, 2026. The options were awarded at an exercise price of $0.00 per share as part of his compensation.
The option grant will vest in full on February 19, 2027, as long as Gray continues to serve the company through that vesting date. After this grant, he holds derivative securities representing 29,561 shares directly.
Generate Biomedicines, Inc. reported multiple insider-related transactions involving funds affiliated with Flagship Pioneering. On March 2, 2026, shares of Series A, B and C preferred stock held by these funds automatically converted into common stock on a one-for-1.5190 basis upon the closing of the company’s initial public offering. On the same date, Flagship Pioneering Fund VII, L.P., FPN II, L.P. and Pioneering Medicines 02, LLC each bought 1,562,500 shares of common stock at $16 per share in open-market or private transactions, for a total of 4,687,500 shares purchased. Separately, on February 26, 2026, Noubar Afeyan received a grant of 29,561 stock options that vest in full on February 19, 2027, subject to continued service.